Assesses the percentage of children and adolescents with ongoing antipsychotic medication use who had metabolic testing during the year.
Why It Matters
Antipsychotic medication prescribing in children and adolescents has increased rapidly in recent decades.1,2 These medications can increase a child’s risk for developing serious metabolic health complications3,4 associated with poor cardiometabolic outcomes in adulthood.5 Given these risks and the potential lifelong consequences, metabolic monitoring is important to ensure appropriate management of children and adolescents on antipsychotic medications.
Metabolic Monitoring for Children and Adolescents on Antipsychotics
|Year||Commercial HMO||Commercial PPO||Medicaid HMO|
- Patten, S.B., W. Waheed, L. Bresee. 2012. “A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents.” Canadian Journal of Psychiatry 57:717–21.
- Cooper, W.O., P.G. Arbogast, H. Ding, G.B. Hickson, D.C. Fuchs, and W.A. Ray. 2006. “Trends in prescribing of antipsychotic medications for US children.” Ambulatory Pediatrics 6(2):79–83.
- Correll, C. U., P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra. 2009. “Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.” Journal of the American Medical Association
- Andrade, S.E., J.C. Lo, D. Roblin, et al. December 2011. “Antipsychotic medication use among children and risk of diabetes mellitus.” Pediatrics 128(6):1135–41.
- Srinivasan, S.R., L. Myers, G.S. Berenson. January 2002. “Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study.” Diabetes 51(1):204–9.